Smith+Nephew to showcase advanced Orthopaedic Handheld Robotics, Reconstruction and Trauma technologies during AAOS 2026
Rhea-AI Summary
Smith+Nephew (NYSE:SNN) will showcase handheld robotics, digital planning and trauma/extremities implants at AAOS 2026 in New Orleans, March 3-6, 2026, Booth #839.
Highlights include the CORI handheld robotics ecosystem and new CORI SHOULDER cases, EVOS plating, TRIGEN MAX tibial nailing, ASC enterprise solutions and new distribution partnerships.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SNN was down 3.09% while key medical device peers were mixed: ZBH up 2.2%, PHG up 0.16%, PODD up 0.6%, STE down 0.86%, PEN flat. This points to a stock-specific move rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Product showcase | Positive | -3.1% | Highlighted rotator cuff repair portfolio and new systems at AAOS 2026. |
| Feb 24 | Distribution deal | Positive | -0.6% | Exclusive US distribution agreement for A’TOMIC Nitinol Fixation System. |
| Feb 23 | Distribution deal | Positive | -0.6% | Distribution agreement for SI-BONE iFuse TORQ trauma and SI joint solutions. |
| Jan 21 | Acquisition close | Positive | +1.9% | Completed Integrity Orthopaedics acquisition adding Tendon Seam RCR system. |
| Oct 27 | Clinical outcomes data | Positive | +0.3% | Real-world study showed superior PICO sNPWT outcomes and cost reductions. |
Recent operational and portfolio-expansion news has often aligned as positive in tone but coincided with modest share price declines, with only some deals and clinical data triggering small gains.
Over the past several months, Smith+Nephew has focused on expanding its orthopaedics and trauma portfolio and highlighting clinical differentiation. The company completed the Integrity Orthopaedics acquisition on Jan 21, 2026, strengthening shoulder repair and seeing a +1.9% move. Multiple distribution agreements in February 2026 (SI-BONE’s iFuse TORQ and RMR Ortho’s A’TOMIC™) modestly expanded trauma offerings but coincided with small share declines. Ahead of AAOS 2026, SNN highlighted its rotator cuff repair portfolio and again saw a -3.09% reaction, suggesting investors have not consistently rewarded incremental product news.
Market Pulse Summary
This announcement highlights Smith+Nephew’s strategy to deepen its position in orthopaedic reconstruction and trauma, emphasizing the CORI◊ handheld robotics ecosystem, the CORI SHOULDER platform with the AETOS◊ Shoulder System, and expanded trauma offerings such as EVOS◊ and TRIGEN◊ MAX Tibia. Recent distribution agreements and acquisitions have broadened the portfolio, while 2024 sales reached $5.8 billion. Investors may watch adoption of these systems, clinical data, and execution in key markets to gauge long-term impact.
Key Terms
arthroplasty medical
humeral medical
glenoid medical
nitinol technical
AI-generated analysis. Not financial advice.
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will
feature handheld robotics and digital solutions for hip, knee and shoulder in addition to
innovative trauma and extremities products during the American Academy of Orthopaedic Surgeons
(AAOS) Annual Meeting in New Orleans this week. Some of the company’s latest Orthopaedics
advancements and highlighted technologies include:
Handheld Robotics: Optimizing and Personalizing Surgery
As the leader in handheld robotics, the CORI◊ Surgical System delivers a digital surgery
ecosystem–spanning solutions from advanced pre-operative planning and a connected post-operative
data management solution. The entire robotics ecosystem is designed to amplify the surgeon
experience and expertise and has shown improvements in accuracy and patient outcomes in joint arthroplasty.¹,²
Smith+Nephew’s CORIOGRAPH◊ Pre-Op Planning and Modeling Services enables optimization of handheld
robotic knee and shoulder* arthroplasty and computer guided hip – further personalizing surgery for
both surgeons and their patients. CORIOGRAPH Pre-Op Planning and Modeling Services + CORI Surgical
System supports several image modalities - allowing for a new dimension of pre-operative planning
for each individual patient - and supporting the intra-operative surgical workflow.
In the booth at AAOS, Smith+Nephew will have a motion capture lounge demonstrating how 3-D modeling
of patient motion is important in planning implant position and advanced simulated activities of
daily living.
*CORI XT is required for shoulder application
CORI SHOULDER Robotic Shoulder Arthroplasty with the AETOS◊ Shoulder System: Differentiated
Technology for Personalized Care
In the fast-growing shoulder market, the CORI SHOULDER Platform is well positioned to meet the unmet
needs of surgeons who demand both accuracy and procedural efficiency. The system is specifically
optimized for use with the AETOS Shoulder System. It features the CORI Handheld Robotic Platform
technology and supports robotic preparation of both humeral and glenoid execution for shoulder
arthroplasty.
Smith+Nephew advances robotic shoulder arthroplasty with a complete, handheld solution that
supports seamless integration and workflow efficiencies for shoulder arthroplasty.³ The procedure
represents a significant leap forward in the shoulder arthroplasty space, perfectly suited for the
constraints of the anatomy and supported by a portable footprint for flexibility in the hospital or
ASC.
Last week, the first ever CORI SHOULDER Robotic Shoulder Arthroplasty cases were completed,
performed by a surgical team at Duke Health led by Dr. Christopher Klifto. To learn more, please
visit the CORI SHOULDER website or see a live demo of CORI SHOULDER Robotic Shoulder Arthroplasty
at AAOS in Booth #839.
Advanced Implant Science
Get the latest clinical data and insights on our flagship implant options for hip, knee and
shoulder arthroplasty including recent additions to our portfolio such as LEGION◊ Total Knee Medial
Stabilized System, CATALYSTEM◊ Primary Hip System and the AETOS Shoulder System stemless option.
Trauma Advancements
From reduction to fixation, the EVOS◊ LARGE & PERIPROSTHETIC Plating System has evolved to give
surgeons stability and flexibility with one screw design for threaded locking, and variable-angle
locking and compatibility with the EVOS Cabling System. We will also be expanding the EVOS
portfolio this year with the launch of the EVOS PELVIC System.
TRIGEN◊ MAX Tibia Nailing System is the only system to give trauma surgeons the choice of
side-specific (right and left) nails for anatomic screw trajectories, which help to optimize
fragment fixation and minimize soft tissue irritation with headless and low-profile screw
options.⁴,⁵ Come visit Smith+Nephew at Booth #839 and hear about the expansion of TRIGEN MAX Tibia
this year.
Smith+Nephew has also recently signed distribution agreements with SI-BONE, focused on their
innovative iFuse TORQ portfolio for pelvic fractures and RMR Ortho for the A’TOMIC™ Nitinol
Fixation System, a compression fixation option for trauma cases.
ASC Portfolio: Expanded Enterprise Offering
At the ASC suite, Smith+Nephew will provide customers with a preview of our expanded enterprise ASC
offering—an end-to-end solution designed to support both de novo ASC development and the
modernization of existing facilities. This comprehensive model enables customers to finance,
design, build, equip, and optimize their centers through one coordinated, streamlined pathway.
Through new strategic partnerships with Brasfield & Gorrie, Ghafari Associates, Unity Health
Centers, and STERIS, we are bringing best-in-class expertise and technologies together into a
single, aligned delivery model—helping customers accelerate timelines, reduce complexity, and drive
operational performance from day one.
To learn more about Smith+Nephew’s advanced solutions for orthopaedic reconstruction, please visit
Booth #839 at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in New Orleans, LA
March 3-6, 2026 or visit www.smith-nephew.com
- ends –
References:
1. Bollars P, Janssen D, De Weerdt W, et al. Improved accuracy of implant placement with an
imageless handheld robotic system compared to conventional instrumentation in patients undergoing
total knee arthroplasty: a prospective randomized controlled trial using CT-based assessment of
radiological outcomes. Knee Surg Sports Traumatol Arthrosc. 2023;31(12):5446-5452.
2. Bollars P, Nathwani D, Albelooshi A, et al. Imageless handheld robotic-assisted total knee
arthroplasty showed better clinical outcomes than conventional total knee arthroplasty: A
randomized controlled trial with preliminary results at 1-year follow up. Knee.
2025;56(10):232-240.
3. Smith+Nephew 2025. Internal Report. 10158129
4. Smith+Nephew 2023. Internal Report 10092864 Ver A.7. I20-4GEN-A Verification Activity - TRIGEN
MAX Tibial Nail
5. Smith+Nephew 2023. Internal Report 10092852 Ver A. I20-4GEN-A Verification Activity - Screw
Prominence]
Media Enquiries
Gina Kamler
+1 (901) 262-9070
Smith+Nephew
gina.kamler@smith-nephew.com
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by
using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000
employees deliver this mission every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and application of new technologies across
our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound
Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of
‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated
subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X,
LinkedIn, Instagram or Facebook. For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For
example, statements regarding expected revenue growth and trading profit margins, market trends and
our product pipeline are forward-looking statements.
Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are generally intended to identify
forward-looking statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to differ materially from
what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and customers; price levels for established
and innovative medical devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product defects or recalls or other problems
with quality management systems or failure to comply with related regulations; litigation relating
to patent or other claims; legal and financial compliance risks and related investigative, remedial
or enforcement actions; disruption to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including acquisitions and disposals, our
success in performing due diligence, valuing and integrating acquired businesses; disruption that
may result from transactions or other changes we make in our business plans or organisation to
adapt to market developments; relationships with healthcare professionals; reliance on information
technology and cybersecurity; disruptions due to natural disasters, weather and climate change
related events; changes in customer and other stakeholder sustainability expectations; changes in
taxation regulations; effects of foreign exchange volatility; and numerous other matters that
affect us or our markets, including those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S.
Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended,
including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s
website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking
statement is based on information available to Smith+Nephew as of the date of the statement. All
written or oral forward-looking statements attributable to Smith+Nephew are qualified by this
caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
FAQ
What is Smith+Nephew (SNN) presenting about CORI handheld robotics at AAOS 2026?
When were the first CORI SHOULDER robotic shoulder arthroplasty cases completed for SNN's CORI SHOULDER?
What trauma products will Smith+Nephew (SNN) feature at AAOS 2026 and why do they matter?
What does Smith+Nephew's expanded ASC enterprise offering mean for ambulatory surgery centers?
Has Smith+Nephew (SNN) announced any new partnerships or distribution deals at AAOS 2026?
